-
We know mental health can affect those living with a brain tumour, but are we doing enough?
Ally Rooney posts an open letter to doctors, nurses, and allied health professionals who care for people with a brain tumour.
-
How has DevoManc affected The Brain Tumour Charity?
Last year, Greater Manchester became the first English region to gain control of health spending. Read our view on the impact this has had on charities.
-
Encouraging results for new clinical approach to glioblastoma treatments
Researchers at McGill University Health Centre (MUHC), Montreal have developed a new clinical approach to enhance the efficiency of treatment for glioblastomas, which increased the average survival time to 22 months.
-
Glasgow’s £32m Imaging Centre of Excellence has now opened
The Imaging Centre of Excellence (ICE), was opened last Wednesday at the University of Glasgow, with the aim to be a global hub for precision medicine.
-
Diageo dinner in memory of much-loved colleague
Diageo chose to support The Brain Tumour Charity following the sudden death of much loved colleague Mark Richardson.
-
Gene-editing techniques give new insight on key protein involved in medulloblastoma development
Researchers at St. Jude Children’s Research Hospital, USA have revealed how a key protein involved in driving the growth of the most aggressive form of medulloblastoma also plays a role in stopping its development.
-
Pioneering research reveals new genetic errors that lead to an inherited risk of developing glioma
Scientists from The Institute of Cancer Research (ICR) have discovered 13 new genetic errors related with an increased risk of developing glioma in one of the largest ever studies of this devastating disease
-
Our work with House of Lords Select Committee on Charities
On Sunday 26 March, the House of Lords Select Committee on Charities published a report, ‘Stronger charities for a stronger society’, following an inquiry into issues facing the charity sector in England and Wales.
-
New research uncovers a molecule that halts DIPG tumour growth
A team of researchers from Northwestern University, USA have identified a molecule that could be used to inhibit the growth of the most fatal paediatric brain tumour, diffuse pontine intrinsic glioma (DIPG).
-
Delivering equal access to benefits for brain tumour patients
Over the last three years, The Brain Tumour Charity has expressed concerns about the assessment criteria used for Personal Independence Payments (PIPs), and their impact on people affected by a brain tumour.
-
Childhood cancer patients in the UK will miss out on access to clinical trials for new treatments
Many news outlets are today reporting concerns from medical research institutions that childhood cancer patients in the UK will miss out on access to clinical trials for new treatments following Brexit.
-
Recent developments of our Leeds-based research into brain tumour treatment
Dr Thomas Ward, part of the Leeds Institute of Cancer and Pathology research team, is funded by various cancer charities including The Brain Tumour Charity.
-
Is the EAMS failing patients?
Cameron Miller, our Information & Support Services Manager, outlines the growing trend for crowdfunding for treatment funds.
-
Convection enhanced delivery of a water insoluble drug shows early promise in targeting high grade brain tumours
Findings from a study published in the International Journal of Nanomedicine have shown for the first time that the drug Panobinostat can be encapsulated in a water soluble molecule and delivered to a brain tumour to destroy high grade glioma cells.
-
Are women being labelled as mentally ill when in fact the cause of their symptoms is potentially more deadly?
Senior Policy and Public Affairs Manager, Beccy Shortt, discusses the journey many women face to being correctly diagnosed with a brain tumour.
-
Clinical trial using an advanced imaging method could predict sites of glioblastoma tumour progression
A new, promising clinical trial, led by Dr Stephen Price, is opening in the UK to look at how using advanced imaging methods can predict where a glioblastoma tumour is likely to grow back before any treatment is given. This study is the first of its kind to better understand this question.
-
King’s College Hospital trials Virtual Reality MRI scanner app to help patients
Researcher and clinicians at King’s College Hospital in London are trialling a Virtual Reality (VR) app to help children due to undergo an MRI (magnetic resonance imaging).
-
New research shows benefits of precision medicine in treating brain tumours in children
In the largest study of its kind, researchers found that advanced precision medicine has beneficial applications for treating childhood brain tumours.
-
A sibling’s story: When Fleur’s sister Grace was diagnosed, her family world fell apart
Fleur Latter’s sister Grace, was diagnosed with a pilocytic astrocytoma in early 2014 when she was in her third year at University.
-
Cannabis-derived medication shows promise in Phase 2 clinical study
Earlier this week, positive results were released from a clinical study testing a combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) as a treatment in recurrent glioblastoma (GBM) patients in the UK.
-
Revolutionary new smart-needle could transform neurosurgery
Researchers at the University of Adelaide have developed a novel piece of technology that acts as a tiny flashlight, allowing surgeons to see in to the brain. This machinery could transform neurosurgery for both patients and doctors.
-
BBC Children in Need and St James’s Place Foundation award grants to our support services
BBC Children in Need and St James’s Place Foundation have awarded grants totalling over £208,000 to The Brain Tumour Charity’s support services.
-
The Brain Tumour Charity asked to lead on discussions around biobanking and early diagnosis
On Monday The Brain Tumour Charity attended the second meeting of the task and finish working group on research into brain tumour (TFWG) which was set up by the Department of Health to address barriers to research.
-
What Brexit means for research into brain tumours
Policy Officer, James Thorneycroft, discusses how leaving the EU could affect research into brain tumours.